文献速递淋巴瘤白血病

慢性淋巴细胞白血病中的肝功能障碍:患病率、结局与病理发现

Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings.
PubMed 文献 · Am J Hematol · 2017-10-19

在2336例初治慢性淋巴细胞白血病(CLL)患者中,3.5%在诊断时存在肝功能检查(LFT)异常,且与晚期Rai分期、较低血红蛋白和血小板计数相关。诊断时LFT异常者总生存(OS)较短(HR 1.80),但至首次治疗时间(TTFT)无差异;52例肝活检中73%有CLL肝浸润。

要点

  • 初治CLL诊断时LFT异常患病率为3.5%(82/2336)。
  • LFT异常与晚期Rai分期、低血红蛋白和低血小板计数相关。
  • 诊断时LFT异常者OS较短(HR 1.80),但TTFT无差异。

核心结论

  • 约1/25的新诊断CLL患者在诊断时存在LFT异常,这些患者OS较短,但TTFT无差异。

研究设计与样本

  • 回顾性分析1993年9月至2016年4月在Mayo Clinic Rochester就诊的新诊断(<12个月)初治CLL患者,共2336例有基线LFT评估。

主要发现

  • 诊断时LFT异常者82/2336(3.5%),与晚期Rai III-IV期相关(21% vs 6%;P < .001)。
  • LFT异常者血红蛋白较低(13.1 g/dL vs 13.9 g/dL;P < .001),血小板计数较低(187 × 10^9/L vs 200 × 10^9/L;P = .03)。
  • 诊断时LFT异常者OS较短(HR 1.80,95% CI 1.13-2.87;P = .014,校正年龄、性别、Rai分期和治疗),但TTFT无差异。
  • 52例肝活检中39例(73%)肝组织存在CLL浸润,门管区最常受累。
  • CLL肝浸润的组织病理学发现与CLL治疗选择相关性有限。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prevalence of liver dysfunction and its association with outcomes in patients with previously untreated chronic lymphocytic leukemia (CLL) is unknown. Newly diagnosed (<12 months) previously untreated CLL patients seen at Mayo Clinic, Rochester, MN between 9/1993 and 4/2016 who had baseline assessment of at least one liver function test (LFT) were included in this analysis. The prevalence of liver dysfunction at baseline, proportion of patients who acquired LFT abnormalities, time to first therapy (TTFT) and overall survival (OS) were assessed. An abnormal LFT was present in 82/2336 (3.5%) patients at diagnosis and was associated with advanced Rai stage (Rai III-IV) (21% vs. 6%; P < .001), lower hemoglobin (13.1 g/dL vs. 13.9 g/dL; P < .001), and lower platelet count (187 × 109/L vs. 200 × 109/L; P = .03). Additionally, 236 patients with normal LFTs at diagnosis developed acquired liver dysfunction during follow-up. Patients with abnormal LFTs at diagnosis had a shorter OS compared to those with normal LFTs (HR 1.80 95% CI 1.13-2.87; P = .014, adjusted for age, sex, Rai stage, and treatment), although TTFT was not different. Of 52 patients who underwent a liver biopsy, CLL was present in liver tissue in 39/52 (73%) patients, with the portal tracts the most common region involved. Histopathology findings of liver involvement by CLL had limited correlation with choice of CLL therapy. In conclusion, approximately 1 of 25 newly diagnosed CLL patients has abnormal LFTs at diagnosis. Although the TTFT was not different among patients with abnormal LFTs, these patients have a shorter OS compared to those with normal LFTs.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Hampel PJ, Chaffee KG, King RL, et al. Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. Am J Hematol. 2017. PMID: 28940587. doi:10.1002/ajh.24915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。